<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908192</url>
  </required_header>
  <id_info>
    <org_study_id>SNR-01-NaBen</org_study_id>
    <nct_id>NCT01908192</nct_id>
  </id_info>
  <brief_title>Adaptive Phase II Study to Evaluate the Safety &amp; Efficacy of NaBen®</brief_title>
  <official_title>An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SyneuRx International (Taiwan) Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SyneuRx International (Taiwan) Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment
      for schizophrenia in adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part, multi-center, prospective, randomized, placebo-controlled, parallel-group
      study, in which adolescent subjects with schizophrenia will be enrolled. Overall, eligible
      subjects will be randomized in a pre-defined 1:1 ratio to NaBen® or placebo.

      This study will be conducted in two parts:

      In Part 1 (Phase IIb) of the study, 76 subjects (~ 60% of the total planned subjects) will be
      randomized in a 1:1 ratio (NaBen® or placebo), of which 38 subjects will be randomized to the
      NaBen® group and 38 subjects to the placebo group. An interim analysis (IA) will be conducted
      after the randomization of the 76th subject in Part 1 of the study. The data will be analyzed
      after all enrolled subjects in Part 1 of the study complete Visit 5 (week 6) or are withdrawn
      from the study, whichever occurs first. The data from IA will be reviewed by an independent
      Data Safety and Monitoring Committee (DSMC) that will be responsible for the review of the
      data from the Part 1 (Phase IIb) of the study for both safety and the effectiveness.

      In Part 2 (Phase III) of the study, a total of 50 subjects will be randomized, of which 25
      subjects will be randomized to the NaBen® group and 25 subjects to the placebo group. The
      final subject numbers in the study will depend on the sample size re-estimation after Part 1
      of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score after 6 weeks of treatment</measure>
    <time_frame>Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Positive and Negative Syndrome Scale (PANSS) total score from baseline after 6 weeks of treatment</measure>
    <time_frame>Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with 20% or more reduction in Positive and Negative Syndrome Scale (PANSS) total score from baseline after six (6) weeks of treatment</measure>
    <time_frame>Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Positive and Negative Syndrome Scale (PANSS) sub-scales</measure>
    <time_frame>Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Scale for Assessment of Negative Symptoms (SANS) total scores</measure>
    <time_frame>Scale for Assessment of Negative Symptoms will be assessed at Visit 1 (Screening), Visit 3,4,5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Scale for Assessment of Negative Symptoms (SANS) sub-scale scores</measure>
    <time_frame>Scale for Assessment of Negative Symptoms will be assessed at Visit 1 (Screening), Visit 3,4,5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in the PANSS total score after 6 weeks of treatment</measure>
    <time_frame>Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent change in Children's Global Assessment Scale (CGAS)</measure>
    <time_frame>Children's Global Assessment Scale will be assessed at Visit 1(Screening), Visit 3, 4, 5, and 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in Clinical Global Impression-Severity (CGI-S)</measure>
    <time_frame>Clinical Global Impression will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in Children's Depression Rating Scale-Revised (CDRS-R)</measure>
    <time_frame>Children's Depression Rating Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>NaBen®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NaBen® is a white oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control treatment is placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaBen®</intervention_name>
    <description>The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).</description>
    <arm_group_label>NaBen®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects who are between 12 and 17 years of age inclusive

          -  Physician confirmed DSM-IV or -V diagnosis of schizophrenia based on MINI
             International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders
             Studies for Children and Adolescents, version 6.0 (MINI-KID, Version 6.0)

          -  Are clinically stable with residual symptoms, defined as a total score of ≥ 60 of
             PANSS and a score of ≥ 40 for SANS

          -  An unchanged antipsychotic medication regimen for at least eight (8) weeks prior to
             randomization into the study and expected to remain unchanged during the study (longer
             for depot or long-acting antipsychotics: ten (10) months for Aripiprazole (Maintena®)
             and Paliperidone (Xeplion®); six (6) months for Olanzapine pamoate monohydrate
             (Zypadhera®); and at least 6 times duration of the reported half life or minimum four
             (4) months for other depot or long-acting antipsychotics)

          -  In good general physical health and all physical exam, neurological exam and
             laboratory assessments (urine/blood routine, biochemical tests and ECG) are clinically
             unremarkable per the investigator

          -  Subject has a negative urine illicit drug screening test

          -  Subject understands and is willing to sign the Informed Assent Form (IAF) prior to
             study entry and agrees to be available for all the study visits

          -  The subject's guardian understands and is willing to sign the Informed Consent Form
             (ICF) prior to study entry and agrees to be available for all the study visits

          -  Must not be a danger to self or others and must have family support available to be
             maintained as outpatients

        Exclusion Criteria:

          -  Meets the DSM-IV or -V criteria at screening for mental retardation, dissociative
             disorder, bipolar disorder, major depressive disorder, schizoaffective disorder,
             schizophreniform disorder, autistic disorder, or primary substance induced psychotic
             disorder. Other comorbid disorders; e.g., attention-deficit hyperactivity disorder
             (ADHD), are allowed as long as schizophrenia is the primary diagnosis and the comorbid
             disorder(s) do not require medication.

          -  Subjects whose illness was resistant to antipsychotics according to prior trials of
             two different antipsychotics of adequate dose

          -  History of epilepsy, head trauma, or neurological illness other than Tourette's
             syndrome

          -  History of allergic reaction to sodium benzoate

          -  Serious medical illnesses such as acute or chronic renal disease, liver failure or
             heart disease that, in the opinion of the investigator, may interfere with the conduct
             of the study.

          -  Current substance abuse or positive urine illicit drug screening or history of
             substance dependence (including alcohol, but excluding nicotine and caffeine) in the
             past three (3) months.

          -  Use of depot antipsychotics in the past six (6) months

          -  Inability to follow protocol

          -  Body Mass Index (BMI) &gt; 35

          -  Female subjects who are pregnant (as confirmed by urine pregnancy test performed at
             screening Visit) or are nursing, or who do not agree to abstinence or birth control
             during the study

          -  Cancer within the last three (3) years except for basal cell carcinoma and squamous
             cell carcinoma

          -  Previous participation in an intervention trial within 30 days of randomization

          -  Subjects whose PANSS score has decreased more than 10 percent during the Screening
             Phase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Findling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yashar Salek, MD</last_name>
    <phone>1-301-956-2527</phone>
    <email>yashars@amarexcro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anand Balasubramanian, B Pharm.</last_name>
    <phone>1-301-956-2531</phone>
    <email>anandb@amarexcro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Harmonex Neuroscience Research</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Handal, MD</last_name>
      <phone>334-836-2000</phone>
      <email>nhandal@harmonex.us</email>
    </contact>
    <investigator>
      <last_name>Nelson Handal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CiTrials</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Zarate-Rowell, MD</last_name>
      <phone>562-748-4999</phone>
      <email>ezrowellmd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Zarate-Rowell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renew Behavioral Health, Inc.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laja Ibraheem, MD</last_name>
      <phone>562-426-5222</phone>
      <email>likita82@aol.com</email>
    </contact>
    <investigator>
      <last_name>Laja Ibraheem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CiTrials</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Maguire, MD</last_name>
      <phone>951-300-4927</phone>
      <email>gerald.maguire@ucr.edu</email>
    </contact>
    <investigator>
      <last_name>Gerald Maguire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Living/Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Goethe, MD</last_name>
      <phone>860-545-7118</phone>
      <email>john.goethemd@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>John Goethe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Health System</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adelaide S Robb, MD</last_name>
      <phone>202-476-3042</phone>
      <email>Arobb@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Adelaide S Robb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Mantero-Atienza, MD</last_name>
      <phone>305-392-0279</phone>
      <email>emantero@bellsouth.net</email>
    </contact>
    <investigator>
      <last_name>Emilio Mantero-Atienza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adly Thebaud, MD</last_name>
      <phone>386-775-7627</phone>
      <email>athebaud@mrgcf.com</email>
    </contact>
    <investigator>
      <last_name>Adly Thebaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Riesenberg, MD</last_name>
      <phone>404-881-5800</phone>
      <email>Rriesenberg@acmr.org</email>
    </contact>
    <investigator>
      <last_name>Robert Riesenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins University - Hugo W Moser Research Institute at Kennedy Krieger Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert L Findling, MD, MBA</last_name>
      <phone>443-923-7620</phone>
      <email>rfindli1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Robert L Findling, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School - Psychiatry Department</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean A Frazier, MD</last_name>
      <phone>774-455-4100</phone>
      <email>Jean.Frazier@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Jean A Frazier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Clinical Research Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RP Rajarethinam, MD</last_name>
      <phone>734-846-2898</phone>
      <email>rpmmc@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>RP Rajarethinam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center - Department of Psychiatry</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjiv Kumra, MD</last_name>
      <phone>612-273-9775</phone>
      <email>kumra002@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Kumra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Kwentus, MD</last_name>
      <phone>601-420-5810</phone>
      <email>jkwentus@precise-research.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Kwentus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Atkinson, MD</last_name>
      <phone>585-241-9670</phone>
      <email>sda@flclinical.com</email>
    </contact>
    <investigator>
      <last_name>Sarah Atkinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati - Dept. of Psychiatry and Behavioral Neuroscience</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Delbello, MD</last_name>
      <phone>513-558-5847</phone>
      <email>DELBELMP@UCMAIL.UC.EDU</email>
    </contact>
    <investigator>
      <last_name>Melissa Delbello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nora McNamara, MD</last_name>
      <phone>216-844-5259</phone>
      <email>nora.mcnamara@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Nora McNamara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Focus and Balance LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariel De Llanos, MD</last_name>
      <phone>210-858-9980</phone>
      <phone_ext>107</phone_ext>
      <email>adellanos1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ariel De Llanos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Institute of Medical Sciences</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <zip>98011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syed J Mustafa, MD</last_name>
      <phone>425-949-5779</phone>
      <email>pi@pspc.org</email>
    </contact>
    <investigator>
      <last_name>Syed J Mustafa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zain Research, LLC</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheta Nand, MD</last_name>
      <phone>509-420-5053</phone>
      <email>zainresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Cheta Nand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital (Linkou)</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiu Feng Lin (林), BA</last_name>
      <phone>+886-3-328-1200</phone>
      <phone_ext>3815</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Hsin Yi Dai, BA</last_name>
      <phone>+886-3-328-1200</phone>
      <phone_ext>8539</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Hsin Yi Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu Hsu Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei Chih Chin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital (Taipei)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsin Yi Dai （戴）, BA</last_name>
      <phone>+886-3-3281200</phone>
      <phone_ext>8539</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Chiu Feng Lin</last_name>
      <phone>+886-3-328-1200</phone>
      <phone_ext>3815</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Yu Hsu Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsin Yi Liang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veteran General Hospital Taipei</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shi Hui Wang (王), BA</last_name>
      <phone>＋886-28757027</phone>
      <phone_ext>305</phone_ext>
    </contact>
    <investigator>
      <last_name>Yin Chao Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai Ling Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ju Wei Hsu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mu Hong Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amarexcro.com</url>
    <description>The clinical trial management organization</description>
  </link>
  <link>
    <url>http://www.syneurx.com</url>
    <description>Sponsor</description>
  </link>
  <link>
    <url>http://syneurx.net</url>
    <description>Trial Background</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sodium Benzoate</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Adolescent</keyword>
  <keyword>Antipsychotic</keyword>
  <keyword>Anti-psychotic</keyword>
  <keyword>NMDA</keyword>
  <keyword>NaBen</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

